CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
about
CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@en
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@nl
type
label
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@en
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@nl
prefLabel
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@en
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@nl
P2093
P2860
P1433
P1476
CTLA-4 polymorphisms are assoc ...... ing bortezomib-based regimens.
@en
P2093
Guo-Xuan Li
Kai-Yan Liu
Lan-Ping Xu
Xiao-Ying Qin
Ying-Jun Chang
Zheng-Fan Jiang
P2860
P304
P356
10.1007/S00277-017-3203-7
P50
P577
2017-12-21T00:00:00Z